We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+59.82%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.55B
AUM Growth
+$107M
Cap. Flow
-$72.8M
Cap. Flow %
-4.7%
Top 10 Hldgs %
49.99%
Holding
236
New
61
Increased
26
Reduced
57
Closed
43

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$20.1M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$17.8M
3
RDUS
Radius Health, Inc.
RDUS
+$15.9M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$14.4M
5
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$13.6M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$45.8M
2
TSRO
TESARO, Inc.
TSRO
+$43.1M
3
NVRO
NEVRO CORP.
NVRO
+$31.9M
4
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$25.3M
5
STJ
St Jude Medical
STJ
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.62%
2 Miscellaneous 2.58%
3 Consumer Staples 0.5%
4 Technology 0.1%
5 Consumer Discretionary 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DSCI
176
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$14K ﹤0.01%
2,970
-429,914
-99% -$2.01M
CAPR icon
177
Capricor Therapeutics
CAPR
$498M
$13K ﹤0.01%
400
– –
CDMO
178
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$10K ﹤0.01%
3,476
-28,571
-89% -$76.7K
INGN icon
179
Inogen
INGN
$138M
$7K ﹤0.01%
125
– –
AVGR
180
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
0
– –
DCOY
181
Decoy Therapeutics
DCOY
$1.78M
– –
0
– –
EGRX
182
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3K ﹤0.01%
544,770
+244,770
+82% +$13.6M
AORT icon
183
Artivion
AORT
$1.24B
$2K ﹤0.01%
+123
New +$1.86K
MD icon
184
Pediatrix Medical
MD
$2.17B
$2K ﹤0.01%
+29
New +$1.98K
SGMO
185
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1K ﹤0.01%
+272
New +$1.38K
TNGN
186
DELISTED
TENGION INC COM NEW STK (DE)
TNGN
$1K ﹤0.01%
1,826,399
– –
ABBV icon
187
AbbVie
ABBV
$465B
– –
-1,250
Closed -$77K
ARCT icon
188
Arcturus Therapeutics
ARCT
$450M
– –
-146,896
Closed -$4.62M
ATRA icon
189
Atara Biotherapeutics
ATRA
$94.8M
– –
-100
Closed -$56K
BCLI
190
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-26,667
Closed -$964K
CLDX icon
191
Celldex Therapeutics
CLDX
$3.02B
– –
-4,742
Closed -$312K
CNC icon
192
Centene
CNC
$33.4B
– –
-9,896
Closed -$353K
CORT icon
193
Corcept Therapeutics
CORT
$12B
– –
-11,000
Closed -$60K
CTMX icon
194
CytomX Therapeutics
CTMX
$586M
– –
-742,021
Closed -$7.58M
DVAX
195
DELISTED
Dynavax Technologies
DVAX
– –
-2,499
Closed -$35.9K
ELDN icon
196
Eledon Pharmaceuticals
ELDN
$220M
– –
-4,081
Closed -$3.64M
GMED icon
197
Globus Medical
GMED
$10B
– –
-50,000
Closed -$1.19M
HEDJ icon
198
PUT
WisdomTree Europe Hedged Equity Fund
HEDJ
$1.76B
– –
-400,000
Closed -$10.1M
HLF icon
199
Herbalife
HLF
$1.25B
– –
-2,500
Closed -$73K
IONS icon
200
PUT
Ionis Pharmaceuticals
IONS
$7.85B
– –
-100,000
Closed -$2.33M
6 7
8
9 10

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Perceptive Advisors held 236 positions worth $1.55B, up 7.4% from $1.44B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $72.8M in Q3 2016, closing 43 positions and reducing 57 holdings. Its most notable exit was MEDIVATION, INC., an estimated $45.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 79% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Kadmon Holdings, Inc. worth $16.2M.

  • Perceptive Advisors's largest Q3 2016 buy was Kadmon Holdings, Inc.: 2,209,657 shares worth $16.2M.
  • Perceptive Advisors added most to Aravive, Inc. Common Stock in Q3 2016, an estimated $14.4M increase.
  • Perceptive Advisors's biggest Q3 2016 reduction was TESARO, Inc., cutting an estimated $43.1M.
  • Perceptive Advisors fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $45.8M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.55B portfolio in Q3 2016.
  • Perceptive Advisors opened 61 new positions and closed 43 in Q3 2016.
  • Perceptive Advisors's portfolio value rose 7.4% quarter-over-quarter to $1.55B.

Based on Perceptive Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.